EcoDrugPlus

Janus Kinase 2b

Ensembl ID : ENSOKIG00005021260
Gene Symbol: JAK2B
1 Cross references
194 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSOKIG00005021800
Gene Symbol: LYN
1 Cross references
189 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSOKIG00005019586
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:

Map Kinase-Activated Protein Kinase 2

Ensembl ID : ENSOKIG00005034502
Gene Symbol: LOC109907733
3 Cross references
168 Possible Orthologues:

Map Kinase-Activated Protein Kinase 5

Ensembl ID : ENSOKIG00005007376
Gene Symbol: LOC109875420
3 Cross references
174 Possible Orthologues:

Map Kinase-Interacting Serine/threonine-Protein Kinase 2-Like

Ensembl ID : ENSOKIG00005031885
Gene Symbol: LOC109882129
3 Cross references
155 Possible Orthologues:

Map Kinase-Interacting Serine/threonine-Protein Kinase 2-Like

Ensembl ID : ENSOKIG00005040517
Gene Symbol: LOC109902574
3 Cross references
202 Possible Orthologues:

Map Kinase-Interacting Serine/threonine-Protein Kinase 2-Like

Ensembl ID : ENSOKIG00005043977
Gene Symbol: LOC109897912
3 Cross references
202 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSOKIG00005024446
Gene Symbol: MAPKAPK2
3 Cross references
187 Possible Orthologues:

Mapk Activated Protein Kinase 2b

Ensembl ID : ENSOKIG00005006524
Gene Symbol: MAPKAPK2B
1 Cross references
168 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSOKIG00005038172
Gene Symbol: MAPKAPK5
3 Cross references
173 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSOKIG00005021814
Gene Symbol: MCL1B
1 Cross references
153 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).